Jianxing He
Impact in
- Infectious Diseases top 0.02%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Health Informatics top 0.05%
Papers in
-
- Lung Cancer Diagnosis and Treatment 160
- Lung Cancer Treatments and Mutations 127
- Tracheal and airway disorders 45
- Pleural and Pulmonary Diseases 40
- Oncology 143
- Lung Cancer Research Studies 64
- Cancer Immunotherapy and Biomarkers 32
- Co-authors
- Wenhua Liang (200 shared papers)Hengrui Liang (119 shared papers)Caichen Li (69 shared papers)Wei Wang (53 shared papers)Jianfu Li (44 shared papers)Wei‐jie Guan (7 shared papers)Ke Xu (9 shared papers)Shiyue Li (8 shared papers)
- Journals
- Translational Lung Cancer Research (56 papers)Annals of Translational Medicine (24 papers)Journal of Thoracic Oncology (22 papers)The Annals of Thoracic Surgery (15 papers)Annals of Oncology (13 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Jianxing He
697 papers receiving 49.1k citations
Jianxing He's Hit Papers
Peers
Comparison fields: 5 of 206
- Infectious Diseases 14.3k
- Health Informatics 1.0k
- Modeling and Simulation 2.3k
- Oncology 11.7k
- Neurology 5.7k
Countries citing papers authored by Jianxing He
This map shows the geographic impact of Jianxing He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianxing He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianxing He more than expected).
Fields of papers citing papers by Jianxing He
This network shows the impact of papers produced by Jianxing He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianxing He. The network helps show where Jianxing He may publish in the future.
Co-authors
The 25 scholars most cited alongside Jianxing He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 737 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical Characteristics of Coronavirus Disease 2019 in China Hit paper breakdown → | 2020 | 21630 |
| 2 | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Hit paper breakdown → | 2020 | 3319 |
| 3 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 4 | The practical implementation of artificial intelligence technologies in medicine Hit paper breakdown → | 2018 | 1609 |
| 5 | Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19 Hit paper breakdown → | 2020 | 1008 |
| 6 | Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions Hit paper breakdown → | 2020 | 1007 |
| 7 | Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography Hit paper breakdown → | 2020 | 695 |
| 8 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 503 |
| 9 | Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 501 |
| 10 | 2020 | 446 | |
| 11 | 2016 | 412 | |
| 12 | Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial Hit paper breakdown → | 2022 | 365 |
| 13 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 311 |
| 14 | 2020 | 278 | |
| 15 | The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis Hit paper breakdown → | 2021 | 275 |
| 16 | 2012 | 274 | |
| 17 | Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry Hit paper breakdown → | 2017 | 273 |
| 18 | 2019 | 214 | |
| 19 | 2020 | 209 | |
| 20 | 2019 | 205 |
About Jianxing He
Jianxing He is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Anesthesiology and Pain Medicine, having authored 737 papers that have together received 50.3k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (160 papers), Lung Cancer Treatments and Mutations (127 papers), Lung Cancer Research Studies (64 papers), Tracheal and airway disorders (45 papers), Pleural and Pulmonary Diseases (40 papers), Cancer Genomics and Diagnostics (37 papers), Transplantation: Methods and Outcomes (36 papers) and Cancer Immunotherapy and Biomarkers (32 papers). The work is most often cited by research in Infectious Diseases (14.3k citations), Health Informatics (1.0k citations), Modeling and Simulation (2.3k citations), Oncology (11.7k citations) and Neurology (5.7k citations). Jianxing He has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Wenhua Liang, Hengrui Liang, Caichen Li, Wei Wang, Jianfu Li, Wei‐jie Guan, Ke Xu, Shiyue Li, Qing Ai and Weixiang Lu. Their work appears in journals such as Translational Lung Cancer Research, Annals of Translational Medicine, Journal of Thoracic Oncology, The Annals of Thoracic Surgery and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.